|Articles|March 2, 2021

WuXi AppTec acquires gene therapy organization

UK-based OXGENE designs and develops scalable gene therapy technologies

WuXi AppTec, a provider of R&D- and manufacturing-enabling services in the pharma, biotech and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organization that designs gene therapy technologies. This deal allows WuXi AppTec to offer support in the design and development of cell and gene therapies for patients in need.

OXGENE will become a fully-owned subsidiary of WuXi Advanced Therapies (WuXi ATU), WuXi AppTec's cell and gene therapy contract testing, development and manufacturing organization (CTDMO) business unit. WuXi ATU's integrated platforms transform the development, testing, manufacturing and commercialization of cell and gene therapy products, and accelerate their time to market. OXGENE, which will keep its name, will be WuXi ATU's first facility in Europe.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.